Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
Aclaris Therapeutics (NASDAQ: ACRS), a clinical-stage biopharmaceutical company specializing in immuno-inflammatory disease treatments, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The company's management team will engage in a fireside chat on Tuesday, December 3, 2024, at 1:00 PM ET in New York.
Interested parties can access the webcast through the 'Events' page in the 'Investors' section of Aclaris' website. The recording will remain available for a minimum of 30 days on www.aclaristx.com.
Aclaris Therapeutics (NASDAQ: ACRS), un'azienda biofarmaceutica in fase clinica specializzata nel trattamento delle malattie immuno-infiammatorie, ha annunciato la sua partecipazione alla 36ª Conferenza Sanitaria Annuale di Piper Sandler. Il team di gestione dell'azienda parteciperà a una chiacchierata informale martedì 3 dicembre 2024, alle 13:00 ET a New York.
Le parti interessate possono accedere alla trasmissione web tramite la pagina 'Eventi' nella sezione 'Investitori' del sito web di Aclaris. La registrazione sarà disponibile per un minimo di 30 giorni su www.aclaristx.com.
Aclaris Therapeutics (NASDAQ: ACRS), una empresa biofarmacéutica en etapa clínica especializada en tratamientos para enfermedades inmuno-inflamatorias, ha anunciado su participación en la 36ª Conferencia Anual de Salud de Piper Sandler. El equipo de gestión de la empresa participará en una charla informal el martes 3 de diciembre de 2024, a la 1:00 PM ET en Nueva York.
Las partes interesadas pueden acceder a la transmisión web a través de la página 'Eventos' en la sección 'Inversores' del sitio web de Aclaris. La grabación estará disponible durante un mínimo de 30 días en www.aclaristx.com.
Aclaris Therapeutics (NASDAQ: ACRS), 면역-염증 질환 치료를 전문으로 하는 임상 단계의 생명공학 회사가 Piper Sandler 제36회 연례 헬스케어 컨퍼런스에 참가한다고 발표했습니다. 회사의 경영진은 2024년 12월 3일 화요일 오후 1시(ET) 뉴욕에서 진행되는 대담에 참여할 예정입니다.
관심 있는 분들은 Aclaris 웹사이트 '투자자' 섹션의 '이벤트' 페이지를 통해 웹캐스트에 접근할 수 있습니다. 녹화는 www.aclaristx.com에서 최소 30일 동안 제공될 것입니다.
Aclaris Therapeutics (NASDAQ: ACRS), une entreprise biopharmaceutique en phase clinique spécialisée dans le traitement des maladies immuno-inflammatoires, a annoncé sa participation à la 36e Conférence Annuelle sur la Santé de Piper Sandler. L'équipe de direction de l'entreprise participera à une discussion informelle le mardi 3 décembre 2024, à 13h00 ET à New York.
Les parties intéressées peuvent accéder au webinaire via la page 'Événements' dans la section 'Investisseurs' du site web de Aclaris. L'enregistrement sera disponible pendant un minimum de 30 jours sur www.aclaristx.com.
Aclaris Therapeutics (NASDAQ: ACRS), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Behandlung immunentzündlicher Erkrankungen spezialisiert hat, hat seine Teilnahme an der 36. Annual Healthcare Conference von Piper Sandler bekannt gegeben. Das Managementteam des Unternehmens wird am Dienstag, den 3. Dezember 2024, um 13:00 Uhr ET in New York an einem informellen Gespräch teilnehmen.
Interessierte Parteien können über die 'Events'-Seite im Abschnitt 'Investoren' der Website von Aclaris auf den Webcast zugreifen. Die Aufzeichnung wird für mindestens 30 Tage unter www.aclaristx.com verfügbar sein.
- None.
- None.
WAYNE, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 1:00 PM ET in New York, New York.
A webcast of the fireside chat may be accessed through the “Events” page of the “Investors” section of Aclaris’ website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.
Aclaris Therapeutics Contact:
investors@aclaristx.com
FAQ
When is Aclaris Therapeutics (ACRS) presenting at the Piper Sandler Healthcare Conference 2024?
How can I watch Aclaris Therapeutics (ACRS) fireside chat at the Piper Sandler Conference?
How long will the Aclaris Therapeutics (ACRS) Piper Sandler Conference webcast be available?
